EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Rosuvastatin Ameliorates the Initiation and Progression of Lung Adenocarcinoma via Facilitating PLK1 Inhibition

Jie Yin, Jianjie Zhu, Yinhua Gong, Wenting Wu, Xinyu Zhang, Chang Li, Yang Yang, Yili Chen, Jianjun Li, Lei Gu, Jian-An Huang, Zeyi Liu und 2 weitere

Frontiers in Bioscience-Landmark · 24.04.2026 · 31 (4)

DOI: 10.31083/fbl49156 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Bioscience-Landmark, online erschienen am 24.04.2026. Verfasst von Jie Yin und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Soochow University, 215006 Suzhou, Jiangsu, China. Hauptthemen laut MEDLINE: Protein Serine-Threonine Kinases, Cell Cycle Proteins, Lung Neoplasms, Proto-Oncogene Proteins. Die Arbeit nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Science and Technology Plan Project of Suzhou, Jiangsu Provincial Medical Key Discipline.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Lung cancer remains a major global public health challenge, with lung adenocarcinoma being the most prevalent histologic subtype. Rosuvastatin, a widely used lipid-lowering agent, has recently attracted attention for its potential antitumor properties. This study investigates the underlying mechanisms and therapeutic potential of rosuvastatin in lung cancer.

Methods

The effects of rosuvastatin were evaluated in lung adenocarcinoma cell lines using Cell Counting Kit-8 (CCK-8), 5-ethynyl-2′-deoxyuridine (EdU) incorporation, Transwell migration and invasion assays, wound-healing assays, and flow cytometry for apoptosis analysis. RNA sequencing identified cell-cycle signaling pathways as the primary targets of rosuvastatin. Analysis of survival curves and differential gene expression between tumor and adjacent non-tumor tissues using public databases, including the Human Protein Atlas, Gene Expression Profiling Interactive Analysis (GEPIA), and Tumor Immune Estimation Resource (TIMER), suggested that polo-like kinase 1 (PLK1) may be a key target mediating the antitumor effects of rosuvastatin. Western blotting and quantitative reverse transcription polymerase chain reaction (qRT-PCR) were used to confirm the differential expression of PLK1 and related cell-cycle proteins in lung adenocarcinoma cells following treatment with different doses of rosuvastatin. Furthermore, rescue experiments with PLK1 knockdown were performed to verify its role in the mechanism of rosuvastatin. A subcutaneous mouse xenograft model was established in vivo to assess the antitumor activity of rosuvastatin via PLK1 inhibition.

Results

Rosuvastatin exerted significant antitumor effects against lung adenocarcinoma both in vitro and in vivo. Mechanistic studies indicated that its anticancer activity is mainly mediated by downregulating PLK1 expression.

Conclusions

By suppressing PLK1 expression, rosuvastatin inhibited cancer cell proliferation, migration, and invasion. These findings support the potential of rosuvastatin as a therapeutic agent for lung cancer, although further studies are needed to confirm its clinical utility.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Protein Serine-Threonine KinasesCell Cycle ProteinsLung NeoplasmsProto-Oncogene ProteinsRosuvastatin CalciumAdenocarcinoma of LungPolo-Like Kinase 1HumansAnimalsMiceCell ProliferationApoptosisCell Line, TumorGene Expression Regulation, NeoplasticXenograft Model Antitumor AssaysCell MovementMice, NudeDisease ProgressionFemale

Stichwörter der Autor:innen

apoptosiscell cyclelung adenocarcinomapolo-like kinase 1rosuvastatin

Substanzen

Polo-Like Kinase 1Protein Serine-Threonine KinasesCell Cycle ProteinsProto-Oncogene ProteinsRosuvastatin Calcium

Autor:innen und Institutionen

  • Department of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Soochow University, 215006 Suzhou, Jiangsu, China.
  • Institute of Respiratory Diseases, Soochow University, 215006 Suzhou, Jiangsu, China.
  • Suzhou Key Laboratory for Respiratory Diseases, 215006 Suzhou, Jiangsu, China.
  • Department of Cancer Diagnosis and Treatment Center, Affiliated Hospital of Jiangnan University, 214000 Wuxi, Jiangsu, China.
  • Department of Pharmacy, The First Affiliated Hospital of Soochow University, 215006 Suzhou, Jiangsu, China.

Förderung

  • Science and Technology Plan Project of Suzhou
  • Jiangsu Provincial Medical Key Discipline

Zitieren

APA

Yin, J., Zhu, J., Gong, Y., Wu, W., Zhang, X., Li, C., Yang, Y., Chen, Y., Li, J., Gu, L., Huang, J. A., Liu, Z., Shen, D., & Zeng, Y. (2026). Rosuvastatin Ameliorates the Initiation and Progression of Lung Adenocarcinoma via Facilitating PLK1 Inhibition. Frontiers in Bioscience-Landmark, 31(4). https://doi.org/10.31083/fbl49156

Vancouver

Yin J, Zhu J, Gong Y, Wu W, Zhang X, Li C, et al. Rosuvastatin Ameliorates the Initiation and Progression of Lung Adenocarcinoma via Facilitating PLK1 Inhibition. Frontiers in Bioscience-Landmark. 2026;31(4). doi:10.31083/fbl49156

BibTeX
@article{Yin2026,
  author = {Yin, Jie and Zhu, Jianjie and Gong, Yinhua and Wu, Wenting and Zhang, Xinyu and Li, Chang and Yang, Yang and Chen, Yili and Li, Jianjun and Gu, Lei and Huang, Jian-An and Liu, Zeyi and Shen, Dan and Zeng, Yuanyuan},
  title = {Rosuvastatin Ameliorates the Initiation and Progression of Lung Adenocarcinoma via Facilitating PLK1 Inhibition},
  journal = {Frontiers in Bioscience-Landmark},
  year = {2026},
  volume = {31},
  number = {4},
  doi = {10.31083/fbl49156}
}
Kostenlos starten →